Y0000744
Dextranomer
European Pharmacopoeia (EP) Reference Standard
Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Scegli un formato
50 MG
107,00 €
Scegli un formato
Cambia visualizzazione
50 MG
107,00 €
About This Item
Prodotti consigliati
Grado
pharmaceutical primary standard
Famiglia di API
dextranomer
Produttore/marchio commerciale
EDQM
applicazioni
pharmaceutical (small molecule)
Formato
neat
Temperatura di conservazione
2-8°C
Descrizione generale
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Applicazioni
Dextranomer EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Confezionamento
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Altre note
Sales restrictions may apply.
Scegli una delle versioni più recenti:
Certificati d'analisi (COA)
Lot/Batch Number
It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documenti section.
Se ti serve aiuto, non esitare a contattarci Servizio Clienti
Possiedi già questo prodotto?
I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.
Injection therapy for reflux: why it works and why it fails.
Andrew J Kirsch
The Journal of urology, 188(1), 16-17 (2012-05-16)
R Angioli et al.
Minerva ginecologica, 60(6), 543-550 (2008-11-05)
Urinary incontinence consist in voluntary urine leakage. Female affected in the world are about 200 thousand. Urinary incontinence affect severely women quality of life. There are different kinds of urinary incontinence that can be treated in different ways. We can
Oliver Schwandner et al.
Surgical innovation, 18(2), 130-135 (2011-01-20)
The aim of this prospective study was to analyze safety and functional outcome of transanal submucosal injection of dextranomer hyaluronic acid ("bulking agents therapy") in patients with passive fecal incontinence. All patients who underwent transanal injection therapy were prospectively enrolled
Editorial comment.
Anthony A Caldamone
The Journal of urology, 188(1), 261-261 (2012-05-19)
Jonathan F Kalisvaart et al.
Journal of pediatric urology, 8(4), 359-365 (2011-08-09)
Follow-up of patients undergoing dextranomer/hyaluronic acid injection for vesico-ureteral reflux (VUR) is controversial. The purpose of our study was to test the hypothesis that patients undergoing the double hydrodistention-implantation technique (Double HIT) have a higher clinical and radiographic success rate.
Filtri attivi
Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..
Contatta l'Assistenza Tecnica.
